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Abstract
Both genomics and environmental stressors play a significant role in increases in blood pressure (BP). In an attempt to further explain
the hypertension (HTN) disparity among African Americans (AA), both genetic underpinnings (selected candidate genes) and stress
due to perceived racial discrimination (as reported in the literature) have independently been linked to increased BP among AAs.
Although Gene x Environment interactions on BP have been examined, the environmental component of these investigations has
focused more on lifestyle behaviors such as smoking, diet, and physical activity, and less on psychosocial stressors such as
perceived discrimination.
The present study uses candidate gene analyses to identify the relationship between Everyday Discrimination (ED) and Major Life
Discrimination (MLD) with increases in systolic BP (SBP) and diastolic BP (DBP) among AA in the Jackson Heart Study. Multiple linear
regression models reveal no association between discrimination and BP after adjusting for age, sex, body mass index (BMI),
antihypertensive medication use, and current smoking status.
Subsequentcandidategeneanalysis identified5SNPs (rs7602215, rs3771724, rs1006502, rs1791926,and rs2258119) that interacted
with perceiveddiscrimination andSBP, and3SNPs (rs2034454, rs7602215, and rs3771724) that interactedwith perceiveddiscrimination
andDBP.Most notably, therewasa significant SNPdiscrimination interaction for 2SNPson theSLC4A5gene: rs3771724 (MLD:SBPP
= .034, DBP P = .031; ED: DBP: P = .016) and rs1006502 (MLD: SBP P= .034, DBP P= .030; ED: DBP P= .015).
This study supports the idea that SNPdiscrimination interactions combine to influence clinically relevant traits such as BP.
Replication with similar epidemiological samples is required to ascertain the role of genes and psychosocial stressors in the
development and expression of high BP in this understudied population.
Abbreviations: AA= African Americans, ARIC= Atherosclerosis Risk in Communities Study, BMI= bodymass index, BP= blood
pressure, CMLDAR = Chronic Major Life Discrimination Attributed to Race, CVD = cardiovascular disease, DBP = diastolic blood
pressure, DISA = Discrimination Instrument, EA = European ancestry, ED = Everyday Discrimination, EDAR = Experiences of
Discrimination Attributed to Race, G  D = Gene  Discrimination interaction, GWAS = Genome-Wide Association Study, HBP =
high blood pressure, HTN = hypertension, HWE = Hardy-Weinberg equilibrium, JHS = Jackson Heart Study, MAF = minor allele
frequency, MDS = multidimensional scaling, MLD = Major Life Discrimination, NSAL = National Survey of American Life, PC =
principal components, SBP = systolic blood pressure, SNP = single nucleotide polymorphism.
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Hypertension (HTN) is a common disease, affecting over 78
million adults in the US every year.[1] African Americans (AA) are
disproportionately affected by this disease, with an earlier age of
onset as well as higher rates of complications than other racial/
ethnic groups.[2] The etiology of HTN is complex and
multifactorial. Studies have identified social, biological, environ-
mental, and genetic risk factors for HTN,[3] but few studies have
considered the ways in which these risk factors interact or work
together in elevating risk among AA. Social factors such as
perceived discrimination related to skin color have been
associated with high blood pressure (HBP) in diverse popula-
tions, especially in low-income groups.[4,5] Further, although self-
reported race has been associated with poor mental and physical
health outcomes in AA,[3] little is known about the degree to
which genetic risk for elevated BP and HTN is shaped by
environmental factors, including psychosocial stressors such as
the experience of unfair treatment-environment interaction that
may exacerbate poor outcomes.
Discrimination is a complex and multidimensional psychoso-
cial stressor. Previous studies have defined the experience of
discrimination as the perception or view that one has been treated
unfairly. Self-report is the most common way of measuring
perceptions of discrimination in survey research.[6] Two of the
more widely used measures of perceived discrimination are
Everyday Discrimination (ED) and Major Life Discrimination
(MLD).[7,8] MLD refers to the experience of unfair treatment
(during one’s lifetime) that might block or forestall social
mobility,[8,9] such as unfair treatment by the police or in the
housing market. ED refers to “daily hassles” that are experienced
in “everyday situations,” such as the frequency of being made to
feel uncomfortable for unfair or unjust reasons, like being treated
with less courtesy in public places than others.
According to the National Survey of American Life (NSAL),
51% of AA have experienced at least some type of ED at least a
few times per month and 59% have experienced a least 1 type of
MLD at some point in their lifetime.[10] Studies also show a linkTable 1
Allele frequencies of relevant SNPs from The 1000 Genomes Project
Gene Chr SNPs Alleles An
NECAP1P2 (pseudogene;
downstream of SLC4A5)
2 rs7581836 T/G
CAPN13 2 rs1879282 C/T
MTHFD2 2 rs1667627 C/T
SLC4A5 2 rs7587117 T/A/C
2 rs10177833 A/C
2 rs7571842 A/G
2 rs2034454 T/G
2 rs4853018 G/A
2 rs7602215 T/C
2 rs3771724 G/A
2 rs1006502 G/A
LOC107986433 5 rs10474346 C/T
KCNQ1 11 rs4930130 A/G
P2RY2 11 rs1791926 C/T
SLC24A4 14 rs11160059 T/C
SLC25A42 19 rs6511018 G/A
19 rs12985799 C/T
C21orf91 21 rs2258119 T/C
AF= allele frequency, African ancestry is AWS (African Ancestry in Southwest US), Chr= chromosome, S
western European ancestry). Genotype data from the Phase 3 May 2013 call set.
2between various measures of discrimination and HTN and
related cardiovascular diseases (CVD).[11–14] These studies
suggest that chronic experiences with discrimination are more
consistently linked to BP and HTN than are subtle or acute
experiences.[15] Although the relationship between genetic
polymorphisms and biological factors such as drug metabolism,
body mass index (BMI), or cardiac structure and function have
been established, how the interaction between genetics and
stressors, such as perceived discrimination, must continue to be
examined. There is evidence of interactions between perceived
discrimination and genetic risk on developing HBP.[13] In a
sample of AA women in the Midwest (N=137), 1 SNP
(rs10177833) on the SLC4A5 gene was found to have a
significant association with skin color on systolic BP (SBP).[16]
This finding was replicated in a sample of 3 generations of West
African women (N=199), where the rs8179526 SNP on the
SLC4A5 gene was associated with SBP.[17] In this study, we use a
targeted candidate gene approach to examine the interaction
between genetic polymorphisms, and perceived racial discrimi-
nation on BP among AA. Specific candidate genes were selected
based on those that have been significantly associated with HBP
previously in the literature as noted previously. The genes and
SNPs proposed for investigation in the present study are those
positional candidate genes that have been found most consistent-
ly to be statistically significantly associated with HBP in previous
studies among AAs. A complete list of the genes and SNPs can be
found in Table 1, and complete full description of functionality
and differences in allele frequency by ancestry can be found in
Taylor et al, 2016.[18] The purpose of the study was to examine
the main effects of gene (SNP) and discrimination on SBP and
diastolic BP (DBP), as well as gene (G) and discrimination (D)
interaction effects (GD) on SBP and DBP. This study extends
the science from examining only individual main effects of
perceived discrimination or genetic underpinnings on BP. Because
it has been well established that genomics and perceived
discrimination alone may contribute significantly to increases
in BP among AAs, this study integrates both genomic and
perceived discrimination interaction effects to advance the science[19].
cestral allele AF in African ancestry AF in European ancestry
T 0.877 0.844
T 0.864 0.763
T 0.820 0.530
T 0.899 0.692
C 0.475 0.616
G 0.656 0.434
G 0.902 0.439
G 0.770 0.601
T 0.770 0.874
A 0.557 0.141
A 0.577 0.141
T 0.713 0.844
A 0.582 0.899
T 0.590 0.980
C 0.902 1.000
G 0.336 0.172
C 0.328 0.167
T 0.656 0.803
NP= single nucleotide polymorphism. European Ancestry is EUA (Utah residence with northern and
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BP. If we can better understand the multiple factors and
interactive effects that contribute to AAs having the highest
incidence and prevalence of HTN in the US, we will be better
equipped to develop more precise individualized interventions to
reduce this health disparity.2. Methods
2.1. Study group
The Jackson Heart Study (JHS) enrolled 5301 AA living in the
metropolitan Jackson, MI area between 2000 and 2004. For this
study, we included only those who had both genotypic and
phenotypic data available for analyses (N=2937), of which 5
participants weremissing SBP andDBP readings, soN=2932was
the final sample size in this report. Adult men and women were
recruited in 4mainways: randomcommunity sampling, volunteer,
family member participants, and through the Atherosclerosis Risk
in Communities Study (ARIC). Participants ranged in age from 21
to 85 years and self-identified as AA. The overall purpose of the
study was to examine genetic, environmental, and social factors
contributing to CVD development in AA. Detailed study design
and methods are discussed elsewhere.[20–23] The University of
Mississippi Medical Center Institutional Review Board provided
ethical approval for the JHS.The JacksonHeart StudyPublications
and Presentations Committee provided approval for this second-
ary analysis study as presented here.3. Measures
3.1. Height, weight, and body mass index
Height was measured by stadiometer and weight by electronic
balance. BMI was calculated using weight in kilograms divided by
height inmeters squared.BMIover25 is definedasoverweight, andTable 2
Creation of summary variables for discrimination, Jackson Heart Stu
Variable Parameterization
ED Mean of 9 questions
(DISA 1a–1i),
categorical responses
ranging from 0 to 6.
“How often on a day-to-day basis do you have
1a. Treated with less courtesy
1b. Less respect
1c. Poor service at restaurants
1d. People think you aren’t smart
1e. People are afraid of you
1f. People think you’re dishonest
1g. You’re not as good as they are
1h. Called names/insulted
1i. Threatened/harassed
MLD Mean of 8 questions
(DISA 4a–11a), yes/
no responses ranging
from 0 to 1.
“Now let’s talk about things that may have hap
religion, physical appearance, sexual orientat
4a. Unfair treatment at school or during train
denied a scholarship, etc)?
5a. Unfair treatment getting a job (ie, not hir
6a. Unfair treatment at work (ie, not promote
7a. Unfair treatment in housing or finding a
wanted or prevented from remaining in a ne
8a. Unfair treatment getting resources or mo
9a. Unfair treatment in medical care (ie, den
care, or could not get care from a medical s
10a. Unfair treatment on the street or in a p
11a. Unfair treatment in getting services (ie,
or by some other service provider)?
DISA= Jackson Heart Study Discrimination Instrument, ED=Everyday Discrimination, MLD=Major Life
3BMI greater than 30 is defined as obese. BMI has been shown to be
a valid predictor of adiposity calculated for weight and height.[24]3.2. Blood pressure readings
BP measurements were taken with random-zero sphygmoman-
ometers and cuffs appropriate for arm size. Three readings were
measured in the right arm after the participant rested in the sitting
position for at least 5minutes according to The Seventh Report of
the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC-7)
guidelines.[25] SBP and DBP were determined by the first and fifth
phase Korotkoff sounds, respectively, with the last 2 BP readings
averaged for the analyses. The diagnosis of HTNwas established
based on average BP levels measured at the study visit (>140/90
mmHg) or a prior diagnosis of HTN and current treatment with
antihypertensive medications. Briefly, during each visit, JHS
participants presented the medications they had taken over the 2
weeks prior to the examination. These included both prescribed
and over-the-counter medications as well as herbal preparations.
For those who did not bring medications to the examination,
medication lists for the participant were obtained by a telephone
call to the participants following the visit or by phone call to the
consenting participant’s pharmacy.[26]3.3. Perceived discrimination
We measured personal experiences with discrimination using the
Discrimination Instrument (DISA), a multidimensional instru-
ment that has also been used in the NSAL.[27] The instrument
measures the occurrence, frequency, attribution, and responses to
discrimination, and has 2 subscales for everyday and MLD. We
followed previous research in operationalizing ED and MLD.[27]
Questions and responses for Everyday (ED) and MLD
are presented in Table 2. ED was assessed via 9 questions aboutdy Discrimination Instrument (DISA).
DISA questions
the following experiences?”
pened over your lifetime because of such issues as your race, ethnicity, gender, age,
ion, or other characteristics. Have you ever felt that you’ve received . . . ”
ing (ie, discouraged by a teacher or advisor from seeking higher education, were
ed or told you could not apply)?
d, overworked/hassled, fired, or unable to get health insurance)?
place to live (ie, prevented from renting/buying a home in the neighborhood you
ighborhood because neighbors made life so uncomfortable)?
ney (ie, denied a bank loan, credit card or some other form of credit)?
ied or provided inferior medical care, made to wait long period of time before getting
pecialist such as a heart doctor)?
ublic place (ie, hassled by police, were the target of public ridicule)?
denied or provided inferior service by a plumber, in a restaurant, the grocery store,
Discrimination.
[31,32]
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from 0 to 6, with higher values corresponding with a greater
frequency of exposure (ie, 0=never, 1= less than a few times a
year, 2=a few times a year, 3=a few times a month, 4=at least
once a week, 5=almost every day, 6= several times a day). The
mean of these responses was used to create a summary scale for
ED. The second scale, MLD, was created using the mean of 8
questions regarding unfair treatment due to a variety of physical
or cultural characteristics, without attribution. These questions
had yes (1) or no (0) coded responses. The overall instrument, as
well as ED and MLD subscales demonstrate good reliability
(Cronbach alpha= .78, .84, and .77, respectively).
In addition to ED andMLD, we further examined participants’
experiences of discrimination related specifically to race: EDAR
(Experiences of Discrimination Attributed to Race) and
CMLDAR (Chronic Major Life Discrimination Attributed to
Race). As respondents were asked to attribute their ED to several
factors, we examined the ED summary scale, and then, created
EDAR to represent those experiences that were attributed to race,
versus those that were attributed to age, gender, weight, or some
other reason. The EDAR is the mean of 9 questions (1a–1i) on the
ED instrument, for those who indicated “race” as the primary
reason for discrimination. Similarly, CMLDAR was created to
represent chronic experiences of MLD that were related to race.
Participants who indicated a higher frequency of discriminatory
experiences (several times a year to a few times a month) were
categorized as “chronic- CMLD,” compared with those who
reported a frequency of a few times a year or less. Among
participants who had chronically experienced discrimination, we
further categorized those who indicated that their experiences
were related to race (and not age, gender, or another factor) as
CMLDAR. CMLDAR is the mean of 4b to 11b for those who
indicated “race” on 13a. Further details on scoring assessment of
EDAR and CMLDAR can be found in Sims et al.[27]3.4. Genotyping
Quality control of genotyped data (SNPs) was performed using
the BROAD genetic analysis platform (GAP) that consists of
PLINK[28] and Birdseed v1.33[29] software. Samples with
genotyping success rate <95%, monomorphic SNPs, 1176 SNPs
that mapped to several loci in the human genome, and SNPs with
minor allele frequency (MAF) <1% were removed for quality
control. We also removed samples with very low heterozygosity
suggesting poor DNA quality and samples with very high
heterozygosity suggesting sample contamination. In addition, we
removed all pairs that shared ≥5% of their genome, as well as
samples that did not cluster well when subjected to multidimen-
sional scaling (MDS) or genome-wide “neighbor” analysis in
PLINK. For the family-based subcohort of the JHS, early
analytical assessment by CARE investigators found little effect on
inflation factor due to familial correlation. Further, we removed
SNPs for which genotype missingness could not be predicted by
surrounding haplotypes. Mendelian inconsistence was checked
for family data using PLINK and the corresponding SNPs were
removed. No SNPs were removed due to significant deviation
from Hardy-Weinberg equilibrium (HWE) because the AA
population is an admixed population, which may result in
departure from HWE.
Genotype imputation performed in CARe has been detailed
elsewhere. Briefly, in CARe, imputation was performed using the
MACH[30] program with HapMap phase 2 (build 36 release 22)
as input. As the AA population is admixed with the proportion of4European ancestry (EA) estimated to be ∼17% to 19%, an
artificial reference panel consisting of equal proportions of the
YRI and CEU HapMap phased haplotypes (using only SNPs
found in both YRI and CEU panels, ie, ∼2.2M SNPs) was
constructed. Hao et al suggested that the accuracy of using the
mixed panel for AAs is comparable to the accuracy reported
when imputing a population of Nigerians using YRI as a
reference panel.[33]
3.5. Statistical methods
Data management, descriptive statistics for the covariates and
outcome variables, and the regression analyses were conducted
using the statistics software program R, version 3.2.3 (http://
www.r-project.org/). Known predictors of BP, such as age, sex,
BMI, antihypertensive use, and smoking status, were assessed in a
multiple linear regressionmodel including all predictors. We used
similar models to assess associations between each perceived
discrimination (including ED and MLD), top 10 principal
components (PCs), and outcome variables (ie, SBP and DBP)
adjusted for age, sex, BMI, antihypertensive use, and current
smoking status. We used the same models to test for the
association between each SNP and the BP phenotypes (ie, SBP
andDBP).We tested each SNP for additive main effects on BP in a
test with 1 degree of freedom.We also tested the SNPperceived
discrimination (ie, ED and MLD) interaction effects of SBP and
DBP using linear mixed models with age, sex, BMI, antihyper-
tensive medication use, and top 10 PCs of the Genome-Wide
Association Study (GWAS) data as covariates. Data manage-
ment, descriptive statistics for the covariates and outcome
variables, and the regression analyses were conducted using the
statistics software package R in version 3.2.3.[34]
To study GeneDiscrimination (GD) interactions on BP
where D represents the perceived discrimination, we applied the
following linear regression model.
Yi ¼ b0 þ b1Zi þ b2Di þ b3SNPi þ b4SNPiDi þ ei ð1Þ
where Yi is the BP outcome (ie, SBP and DBP) for person i; Zi is
a vector of adjustment variables including age, sex, BMI,
antihypertensive medication use, current smoker, and the first 10
PCs of the common genome-wide SNPs; Di is the measure of
perceived discrimination of person i; and SNPi is the additive
genetic effect of any given SNP. b4 represents the effect of SNP
D interaction. In this study, we examined 18 SNPs from 10
candidate genes (Tables 1 and 3) on SBP and DBP in 2932 JHS
AA participants. We also investigated the SNPD interaction
effects on SBP and DBP for women and men separately using the
same statistical model without sex as a covariate.
4. Results
In Table 3, we present descriptive statistics for the 2937 JHS
participants with both phenotypic and genetic data. Five
participants were missing SBP and DBP data, resulting in 2932
participants for examination. The sample had a mean age of 55
years, and the majority of participants was female, obese,
nonsmokers, had HTN, and was on antihypertension medica-
tion. Mean SBP and DBP were 126.8 and 79.1 mm Hg,
respectively. Overall, reports of discrimination reported among
participants were low. The mean ED was 1.08 (range 0–6), mean
EDAR was 0.63 (range 0–6), mean MLD was 0.36 (range 0–1).
To assess the associations between SBP/DBP and known
predictors, we conducted further multiple linear regression
Table 3
Descriptive statistics of the JHS sample with both phenotypic and
genotypic data.
Variable N (non-missing) Mean±SD Median (Q1, Q3)
SBP, mm Hg 2932† 126.8±18.1 125 (114, 137)
DBP, mm Hg 2932† 79.1±10.6 79 (72, 86)
Age, y 2937
∗
55.0±12.8 55.3 (45.0, 64.5)
BMI, kg/m2 2935 32.03±7.48 30.7 (27.0, 35.7)
ED 2918 1.08±1.03 0.89 (0.22,1.64)
MLD 2899 0.368±0.262 0.37 (0.13, 0.50)
EDAR 2935 0.636±0.955 0 (0, 1)
CMLDAR 1436 0.823±11.763 0 (0,0)
Male 2937
∗
38%
Antihypertensive use 2380 62%
Current smoker 2912 14%
Ever smoker 2933 33%
Hypertension 2937
∗
61%
∗
Total sample size of participants with both genomic and phenotypic data N=2937.
† Of the N=2937, 5 participants were missing SBP and DBP, resulting in N=2932.
BMI=body mass index, CMLDAR=Chronic Major Life Discrimination Related to Race, DBP=diastolic
blood pressure, ED=Everyday Discrimination, EDAR=Everyday Discrimination Related to Race,
JHS= Jackson Heart Study, MLD=Major Life Discrimination, SBP= systolic blood pressure, SD=
standard deviation.
Taylor et al. Medicine (2017) 96:43 www.md-journal.comanalyses. We confirmed that older age, male sex, and antihyper-
tensive medication use were significantly associated with both
SBP and DBP (Table 4). BMI and smoking status were
significantly associated with SBP, but not DBP. These 5 variablesTable 4
The summary of multiple regression analysis of systolic (SBP) and d
SBP, mm Hg
Variables Beta coefficient SE P v
Age, y 0.453 0.031 3.30
Male 2.09 0.754 5.64
BMI, kg/m2 0.162 0.051 1.48
Antihypertensive use 3.45 0.79 1.26
Current smoker 4.07 1.09 1.81
The full model is SBP or DBP ∼ age + male gender + BMI + antihypertensive use + current smoker.
BMI=body mass index, DBP=diastolic blood pressure, SBP= systolic blood pressure, SE= standard e
Table 5
The associations of covariates and systolic and diastolic blood pres
SBP, mm Hg
Variables N Beta coefficient SE
ED 2336 0.191 0.362
MLD 2319 1.854 1.355
EDAR 2347 0.139 0.378
CMLDAR 1136 0.026 0.038
PC1 2349 16.528 17.760
PC 2 2349 5.814 18.186
PC 3 2349 9.977 13.097
PC 4 2349 6.766 13.432
PC 5 2349 1.811 13.948
PC 6 2349 12.566 13.950
PC 7 2349 5.005 14.689
PC 8 2349 16.542 13.638
PC 9 2349 1.987 13.715
PC 10 2349 5.729 13.640
Adjusted for age, gender, BMI, antihypertensive use, and current smoking status.
CMLDAR=Chronic Major Life Discrimination Related to Race, ED=Everyday Discrimination, EDAR=Eve
5were consistently used as covariates in the association analyses of
discrimination measures and genetic factors described later.
The association analyses of the 4 discrimination measures with
SBP and DBP adjusted for age, sex, BMI, antihypertensive use,
and current smoking status are presented in Table 5. ED, MLD,
EDAR, and CMLDAR were examined in univariate analyses,
and only ED andMLDwere suggestively associated with SBP and
DBP; thus they were the only 2 variables included in interaction
models. Neither ED norMLDwas independently associated with
SBP or DBP after adjustment for covariates. Additionally, the top
PCs of GWAS data were tested for association with SBP and DBP
(Table 5). At alpha level of 0.05, only PC1 and PC9 were
associated with DBP after adjustment of covariates.
We obtained imputed dosage data of 20 SNPs based on
previously reported candidate genes and SNPs (supplementary
tables, sex stratified, http://links.lww.com/MD/B912). All SNPs
were coded as additive genetic effects. After filtering SNPs with
poor imputed quality (ie, r2<0.8), we tested GD interaction of
18 SNPs, adjusted for age, sex, BMI, antihypertensive medication
use, current smoking status, top 10 PCs of GWAS data, and main
effects of each SNP and discriminationmeasure. The test statistics
including beta coefficient (E), standard error (SE), and P values
(P) of each pair of GD are summarized in Table 6. For SBP
(Table 6A), 5 GMLD interaction terms were associated with
SBP (rs7602215, rs3771724, rs1006502, rs1791926, and
rs2258119) at alpha level of 0.05. However, none of GED
interaction terms were associated with SBP. For DBP, 3 SNPs
(rs2034454, rs7602215 and rs3771724) had consistentlyiastolic (DBP) blood pressure.
DBP, mm Hg
alue Beta coefficient SE P value
1045 0.175 0.019 1.881020
103 4.11 0.45 9.081020
103 0.039 0.030 .19
105 1.68 0.47 3.39104
104 0.419 0.645 .52
rror.
sure.
DBP, mm Hg
P value Beta coefficient SE P value
.598 0.320 0.215 .137
.171 1.317 0.805 .102
.713 0.283 0.225 .209
.488 0.001 0.023 .978
.352 20.756 10.547 .049
.749 7.380 10.806 .495
.446 0.543 7.783 .944
.615 0.602 7.982 .940
.897 10.406 8.286 .209
.368 12.477 8.287 .132
.733 2.949 8.728 .736
.225 3.531 8.106 .663
.885 18.675 8.140 .022
.675 0.792 8.106 .922
ryday Discrimination Related to Race, MLD=Major Life Discrimination, PC=principal components.
Table 6
Association of SNPDiscrimination (GD) interaction with systolic (SBP) (A) and diastolic (DBP) (B) blood pressure.
(A) SBP
ED MLD
SNP GD_E GD_SE GD_P GD_E GD_SE GD_P
rs1879282 0.089 0.674 .895 0.181 2.652 .946
rs1667627 0.882 0.614 .151 1.493 2.462 .544
rs7587117 1.075 0.720 .136 1.825 2.830 .519
rs10177833 0.648 0.539 .229 0.850 2.083 .683
rs7571842 0.706 0.510 .167 0.233 2.064 .910
rs2034454 0.463 0.778 .552 2.726 3.198 .394
rs4853018 1.171 0.647 .070 0.658 2.441 .788
rs7602215 0.872 0.550 .113 4.681 2.052 .023
rs3771724 0.582 0.565 .303 4.354 2.057 .034
rs1006502 0.587 0.564 .298 4.366 2.055 .034
rs7581836 0.761 0.664 .252 2.524 2.594 .331
rs10474346 0.191 0.527 .717 1.963 2.075 .344
rs4930130 0.040 0.540 .941 0.282 2.111 .894
rs1791926 0.528 0.489 .281 4.634 1.913 .015
rs11160059 0.039 0.883 .965 3.535 3.431 .303
rs6511018 0.302 0.520 .561 1.195 2.002 .551
rs12985799 0.213 0.547 .697 1.610 2.062 .435
rs2258119 0.801 0.526 .127 4.480 2.001 .025
(B) DBP
ED MLD
SNP GD_E GD_SE GD_P GD_E GD_SE GD_P
rs1879282 0.327 0.400 .414 0.530 1.573 .736
rs1667627 0.293 0.364 .422 2.079 1.460 .155
rs7587117 0.148 0.427 .729 1.079 1.678 .520
rs10177833 0.153 0.320 .633 0.877 1.235 .478
rs7571842 0.340 0.303 .262 1.821 1.224 .137
rs2034454 0.928 0.461 .044 4.359 1.896 .022
rs4853018 0.139 0.384 .717 0.728 1.448 .615
rs7602215 0.479 0.326 .142 1.776 1.219 .145
rs3771724 0.804 0.335 .016 2.640 1.220 .031
rs1006502 0.814 0.334 .015 2.655 1.219 .030
rs7581836 0.185 0.395 .639 1.181 1.540 .443
rs10474346 0.081 0.313 .796 2.150 1.231 .081
rs4930130 0.223 0.320 .486 0.798 1.252 .524
rs1791926 0.465 0.290 .109 1.138 1.136 .317
rs11160059 0.061 0.524 .907 1.909 2.036 .348
rs6511018 0.043 0.309 .888 1.707 1.187 .151
rs12985799 0.045 0.325 .889 1.977 1.223 .106
rs2258119 0.381 0.312 .222 0.960 1.189 .419
CMLDAR=Chronic Major Life Discrimination Related to Race, DBP=diastolic blood pressure, E=Environment, ED=Everyday Discrimination, EDAR=Everyday Discrimination Related to Race, GD=SNP
Discrimination, MLD=Major Life Discrimination, P=P value, SBP= systolic blood pressure, SE= standard error, SNP= single nucleotide polymorphism.
Taylor et al. Medicine (2017) 96:43 Medicinesignificant interaction effects of both ED and MLD at alpha level
of 0.05. Notably, rs3771724 and rs1006502 had significant G
MLD interaction associated with both SBP and DBP (Table 6A
and B). Supplementary tables are provided for sex-stratified G
D results, http://links.lww.com/MD/B912. Interestingly, the
significant GD identified in the pooled analyses were only
observed in women, not men. In a few cases, the effects were even
more significant in women with a smaller sample size (see
supplementary tables, http://links.lww.com/MD/B912). After
adjusting with Bonferroni methods at a significance threshold
of 0.05, (0.05/18 SNPs=0.0028), we did not identify any
significant interaction effects. The marginally significant inter-
actions account for 0.17% to 0.26% of total variation in BPs. A
supplementary table has been added that includes partial R2
(percent of variance) of all tested SNPs with BP phenotypes,
http://links.lww.com/MD/B912.65. Discussion
This study addressed the paucity of research examining the
GeneDiscrimination interaction on BP in an AA population
using data from the JHS. We identified a number of SNPs prime
for further exploration in SNP-discrimination interactions on BP
among AA.Ourmost robust finding included 2 SNPs (rs3771724
and rs1006502) that showed interaction with MLD on both SBP
and DBP, and ED on DBP in this sample of AAs.
Interestingly, the rs3771724 and rs1006502 loci are linked
(r2=1)[35] and located in the intronic region of the SLC4A5
(NBCe2) gene, previously shown to be associated with BP.[16,35–
39] SLC4A5 is an electrogenic sodium-bicarbonate cotransporter
in the kidney and liver. A mouse model lacking homolog Slc4a5
displays a hypertensive phenotype,[40] which may be a result of
sodium-induced hyperaldosteronism via increased activity of the
Taylor et al. Medicine (2017) 96:43 www.md-journal.comepithelial sodium channel in renal principal cells, though this has
yet to be confirmed in human subjects.[41] High salt concen-
trations in cultured human renal cortical tissue showed increased
SLC4A5 expression compared with low salt conditions in
vitro.[42]
Several studies have similarly reported associations between
the SLC4A5 gene and HBP among AA and European American
(EA) adults. In one study, adults from the University of Virginia
and HyperPath cohorts, polymorphisms in the SLC4A5 gene
were associated with induction of salt-sensitive HTN among
adults of EA ancestry.[43] AA typically have higher rates of salt
sensitivity than EA, and rates of salt-sensitivity among
hypertensive AA men and women have been reported at 73%,
with normotensive AA men and women ranging 36% to 79%,
and normotensive AA women ranging from 43% to 64%.[44]
Genetic polymorphisms, such as SNPs, in the SLC4A5 gene have
also been implicated in BP-related traits, such as resting pulse
pressure, submaximal exercise pulse pressure, submaximal SBP,
and submaximal rate pressure in EA.[35]
One other study reported an association between the rs1006502
(hcv8941031) locus of the SLC4A5 gene and HTN in AA[39] and
with BP in EA.[37] The TT allele, whichwas theminor allele among
their Utah-based population of EA, had a slight increase in plasma
CO2 levels compared with participants with a CT or CC
genotype.[37] Among AAs, the CC genotype is the minor allele,
suggesting this population may have increased risk for elevated
plasma CO2 levels (Table 6). The rs3771724 locus has been
associated with submaximal exercise oxygen consumption
(VO250) and submaximal exercise carbon dioxide expiration
(VCO250) in subjects of EA.
[35] To our knowledge, nomechanism
of action for the genotype at the rs1006502or the rs3771724 locus
on the SLC4A5 gene product has been elucidated.5.1. Strengths
Our data add to the evidence supporting an association between
SNPs in the SLC4A5 gene, and increase in BP is on which a
number of sample populations of AA are reporting similar
results, thus showing the replicability of the SLC4A5 gene
across various samples.[16,36,39] Additional studies point toward
chromosome 2, where SLC4A5 is located, for regions associated
with modulating BP.[45,46] Populations of EAwith the rs1006502
SNP have been shown to be associated with increase in BP[37]:
VO250 and VCO250.
[35] As Hunt and colleagues were only using
Utah residents of EA,[37] and research results published by Stutz
and colleagues reported too few AA participants to be included in
their analyses,[35] further research into how SLC4A5 polymor-
phisms affect AAs, a group with disproportionately high rates of
HTN, is needed. Our data show a GE relationship between
SLC4A5 polymorphisms and racial discrimination in popula-
tions of AAs. Thus, further research into the potential mechanism
of action by which the SLC4A5 gene, particularly the 2 SNPs
rs1006502 and rs3771724, might have a SNP-discrimination
interaction resulting in increases in BP and further explaining the
health disparity between EA and AA population groups is
needed.
This study supports the idea that SNP-discrimination inter-
actions combine to influence clinically relevant traits such as BP.
As AAs in the US experience high levels of both ED andMLD,[7,8]
and (acute and) chronic experiences with discrimination are
consistently linked to HBP and HTN,[15] it is important for
clinicians to be mindful of this SNP-discrimination relationship
when working with AA patients. Furthermore, these analyses7suggest that more work on SNP-discrimination interactions is
required for development and implementation of clinically
relevant protocols for the identification and treatment of HBP
to address a major health disparity affecting AAs.5.2. Limitations
Theuseof self-report perceived racismanddiscriminationmaybea
limitation; however, this is the best noninvasive gold standard
measure of examining racismanddiscrimination.Additionally, the
DISA instrument used here has been validated in other samples of
AAs in the NSAL and JHS. Replication with similar epidemiologi-
cal samples is required to ascertain the role of genes and
psychosocial stressors in the development and expression of
HBP in this understudied population. The addition of other -omic
methodologies such as epigenetic[47] and whole genome sequenc-
ing[48] among under-represented minority populations may also
help to elucidate a more holistic picture of this health disparity.
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